Midkine as a novel target for antibody therapy in osteosarcoma
Midkine as a novel target for antibody therapy in osteosarcoma
复制标题
DOI：
10.1016/j.bbrc.2007.04.183
复制
发表时间：
2007-07-06
影响因子：
3.1
通讯作者：
Naritomi, Kenji
中科院分区：
文献类型：
--
作者：
Maehara, Hiroki;Kaname, Tadashi;Naritomi, Kenji
骨肉瘤是一种预后较差的恶性肿瘤，缺乏准确的预后因素是其难以治愈的原因之一。肝素结合生长因子midkine参与多种肿瘤的发生和发展。然而，midkine与骨肉瘤之间的关系尚不清楚。我们发现midkine在骨肉瘤中过表达，并且midkine的表达水平与预后相关（P < 0.05； log-rank检验）。用抗midkine的功能性抗体治疗，骨肉瘤细胞系9N2、3N1、Saos-2和NOS-1的生长抑制率为未治疗对照的25-65%。我们的研究结果表明，midkine作为预后标志物是有用的，并且是骨肉瘤的候选治疗靶点。(c) 2007爱思唯尔公司版权所有。
Osteosarcoma is a malignant tumor with poor prognosis, and lack of accurate prognostic factors is one of the reasons that make this tumor difficult to cure. The heparin-binding growth factor, midkine is involved in generation and progression of many types of tumors. However, the relationship between midkine and osteosarcoma has been unclear. We show here that midkine is overexpressed in osteosarcoma and the level of midkine expression is correlated with prognosis (P < 0.05; log-rank test). Treatment with functional antibodies against midkine suppresses growth of osteosarcoma cell lines, 9N2, 3N1, Saos-2, and NOS-1, to 25-65% of untreated controls. Our results suggest that midkine is useful as a prognostic marker, and is a candidate therapeutic target for osetosarcomas. (c) 2007 Elsevier Inc. All rights reserved.